Merus B.V. clinical trials
Acquired by Genmab, Dec 12, 2025 · source ↗
The registry lists 9 studies whose lead sponsor is Merus B.V.. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 20, 2026.
Before and after it joined Genmab
- First submitted before Merus B.V. became part of Genmab
- 8
- First submitted after Merus B.V. became part of Genmab
- 1
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Merus B.V.6 studies
- Merus N.V.3 studies
Something wrong with this grouping? Tell us on the Genmab page.
Studies
Recruiting first, then most recently updated. Showing 9 of 9. All Genmab studies →
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid TumorsRecruitingNCT03526835Phase 1/2
Sponsor listed in the registry: Merus B.V. · First submitted before Merus B.V. became part of Genmab
- A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)Active, not recruitingNCT06496178Phase 3
Sponsor listed in the registry: Merus B.V. · First submitted before Merus B.V. became part of Genmab
- A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)Active, not recruitingNCT06525220Phase 3
Sponsor listed in the registry: Merus B.V. · First submitted before Merus B.V. became part of Genmab
- Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung CancerWithdrawnNCT07353957Phase 2
Sponsor listed in the registry: Merus B.V. · First submitted after Merus B.V. became part of Genmab
- Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in CombinationActive, not recruitingNCT04868877Phase 1/2
Sponsor listed in the registry: Merus B.V. · First submitted before Merus B.V. became part of Genmab
- Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid TumorApproved for marketingNCT04100694
Sponsor listed in the registry: Merus N.V. · First submitted before Merus N.V. became part of Genmab
- MCLA-117 in Acute Myelogenous LeukemiaTerminatedNCT03038230Phase 1
Sponsor listed in the registry: Merus B.V. · First submitted before Merus B.V. became part of Genmab
- A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic MalignanciesCompletedNCT03922204Phase 1
Sponsor listed in the registry: Merus N.V. · First submitted before Merus N.V. became part of Genmab
- MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.CompletedNCT03321981Phase 2
Sponsor listed in the registry: Merus N.V. · First submitted before Merus N.V. became part of Genmab